Elcatonin
Also known as: Carbocalcitonin, Eel calcitonin, Eel calcitonin analogue, ELC, Elcitonin, SM-201
Source Elcatonin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Elcatonin is a synthetic eel‑calcitonin analog administered by injection for the treatment of osteoporosis and hypercalcemia, primarily approved in Japan.
Mechanism of Action
Activates calcitonin receptor on osteoclasts, inhibiting bone resorption and lowering serum calcium levels.
Routes of Administration
Goals & Uses
- Osteoporosis treatmentBone MetabolismModerate
- Hypercalcemia managementMineral MetabolismModerate
- Paget's disease of boneBone MetabolismModerate
- Prevention of bone loss in immobilizationBone MetabolismLow
- Analgesic effect in bone painPain ManagementModerate
Contraindications
- Hypersensitivity to elcatonin or calcitonin analoguesAllergyHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Hypersensitivity to calcitoninAllergyHigh
- HypocalcemiaElectrolyte DisorderHigh
Adverse Effects
- Facial flushingCardiovascular/DermatologicCommon
- Allergic reactionsImmunologicalRare
- Injection site reactionsLocalCommon
- FlushingVascularCommonWarmth and redness of the skin
- Nausea and vomitingGastrointestinalCommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- HypocalcemiaMetabolicUncommon
- DizzinessNeurologicUncommonFeeling faint, lightheaded, or unsteady
Drug Interactions
- Loop diureticsModerate
- BisphosphonatesLow
- Calcium supplementsModerate
Population Constraints
- Renal impairmentOrgan ImpairmentRelative
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Lactating womenReproductiveRelative
- Elderly patientsAgeRelative
- ChildrenPediatricAbsolute
Regulatory Status
- European UnionUnapprovedNo EMA approval.
- JPApprovedApproved: osteoporosis, hypercalcemiaMarketed as Elcatonin injection.
- United StatesUnapprovedNot evaluated by FDA.
- United KingdomUnapprovedNot approved in the UK; available primarily in Japan and some Asian markets
Approved in Japan (JP) for osteoporosis; not approved by FDA (US) or EMA (EU).
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Elcatonin?
Elcatonin is a synthetic eel‑calcitonin analog administered by injection for the treatment of osteoporosis and hypercalcemia, primarily approved in Japan.
What is Elcatonin used for?
Elcatonin is educationally associated with: Osteoporosis treatment, Hypercalcemia management, Paget's disease of bone, Prevention of bone loss in immobilization, Analgesic effect in bone pain. Educational only — not medical advice.
How is Elcatonin administered?
Recorded routes of administration: Intramuscular, Subcutaneous.
What are the potential side effects of Elcatonin?
Reported adverse effects include: Facial flushing, Allergic reactions, Injection site reactions, Flushing, Nausea and vomiting, Nausea, Hypocalcemia, Dizziness. This list is not exhaustive — consult a qualified clinician.
Who should avoid Elcatonin?
Recorded contraindications: Hypersensitivity to elcatonin or calcitonin analogues, Pregnancy, Hypersensitivity to calcitonin, Hypocalcemia. Consult a qualified clinician before use.